A Phase 1 interventional study of Levonorgestrel Emergency Pill (BAY86-5028/Opxion) and Levonorgestrel (Postday) in Contraception and Contraception, Postcoital, sponsored by Bayer. Completed at 1 site in Mexico. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-11.
Sponsored by Bayer · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A single dose, two treatments (Postday and Opxion), two periods, two sequences, crossover, randomized, prospective design was chosen with a washout of 21 days between the two study periods. Treatment groups were balanced with the same number of male healthy volunteers who were randomly assigned to the study drug administration sequences.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)
Drug: Levonorgestrel (Postday)
Single dose of 1.5 mg coated tablet
Single dose of two 0.75 mg tablets
Least square estimator of average maximum plasmatic concentration (log transformed)
Time frame: After 2 months
Least square estimator of area under the pharmacokinetic curve (log transformed)
Time frame: After 2 months
Time at which maximum concentration is reached
Time frame: After 2 months
Area under the pharmacokinetic curve from time=0 to time of last blood sample
Time frame: After 2 months
Clearance constant of plasmatic concentration of study drug
Time frame: After 2 months
Half life of plasmatic concentration of study drug
Time frame: After 2 months
Adverse events collection
Time frame: Up to 8 weeks
The record gives a start of Feb 2009, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.